drugset / Trial / NCT01176435

Trial of L-DOPA as a Treatment to Improve Vision in Albinism

NCT01176435

Phase 2 Completed 45 enrolled University of Minnesota
RandomizedParallel-groupDouble-blindTreatment

Summary

This project will evaluate the effect of two doses of levodopa (L-DOPA) in a randomized, placebo-controlled, double-masked clinical trial to see if vision can be improved in individuals with albinism. The hypothesis is that providing L-DOPA to the retinas of these individuals may increase melanin pigment production. Increased melanin has previously been shown to be associated with improved vision.

Timeline

Start
2010-09
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Levodopa Small molecule 0.51 mg/kg Oral
Comparator Levodopa Small molecule 0.76 mg/kg Oral

Indications